Skip to main content
SpringerLink
Log in

Immunosuppressive Agents

Biologic Effects In Vivo and In Vitro

  • Chapter
Lupus

Part of the book series: Contemporary Immunology ((CONTIM))

  • 178 Accesses

Abstract

This chapter reviews information on the biologic effects of immunosuppressive agents used in the treatment of systemic lupus erythematosus (SLE), with a focus on effects on the immune system. Although the connection between such information and the treatment of SLE is not fully understood, certain implications will be proposed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Turk, J. L. and Poulter, L. W. (1972) Selective depletion of lymphoid tissue by cyclophosphamide. Clin. Exp. Immunol. 10, 285–296.

    CAS  PubMed  Google Scholar 

  2. Clements, P. J., Yu, D. T., Levy, J., Paulus, H. E., and Barnett, E. V. (1977) Effects of cyclophosphamide on B-and T-lymphocytes in rheumatoid arthritis. Arthritis Rheum. 17, 347–353.

    Article  Google Scholar 

  3. Hurd, E. R. and Giuliano, V. J. (1975) The effect of cyclophosphamide on B and T lymphocytes in patients with connective tissue diseases. Arthritis Rheum. 18, 67–75.

    Article  CAS  PubMed  Google Scholar 

  4. McCune, W. J., Golbus, J., Zeldes, W., Bohlke, P., Dunne, R., and Fox, D. A. (1988) Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N. Engl. J. Med. 318, 1423–1431.

    Article  CAS  PubMed  Google Scholar 

  5. Dale, D. C., Fauci, A. S., and Wolff, S. M. (1973) The effect of cyclophosphamide on leukocyte kinetics and susceptibility to infection in patients with Wegener’s granulomatosis. Arthritis Rheum. 16, 657–664.

    Article  CAS  PubMed  Google Scholar 

  6. Stockman, G. D., Heim, L. R., and South, M. A. (1973) Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J. Immunol. 110, 277–28.

    CAS  PubMed  Google Scholar 

  7. Poulter, L. W. and Turk, J. L. (1972) Proportional increase in the 0-carrying lymphocytes in peripheral lymphoid tissue following treatment with cyclophosphamide. Nat. New Biol. 238, 17–18.

    Article  CAS  PubMed  Google Scholar 

  8. Winkelstein, A. Effect of immunosuppressive drugs on T and B lymphocytes in guinea pigs. Blood 50, 81–91.

    Google Scholar 

  9. Girard, D., Aloisi, R. M., Bliven, M. L., Cunningham, A. C., and Otterness, I. G. (1990) Cyclophosphamide and 15(S)-15 methyl PGE1 correct the T/B lymphocyte ratios of NZB/NZW mice. Agents Actions. 29, 333–341.

    Google Scholar 

  10. Smith, H. R., Chused, T. M., and Steinberg, A. D. Cyclophosphamide-induced changes in the MRL-1pr/lpr mouse: effects upon cellular composition, immune function, and disease. Clin. Immunol. Immunopathol. 1984. 30, 51–61.

    Article  CAS  PubMed  Google Scholar 

  11. Chiappelli, F., Myers, L. W., Ellison, G. W., Liao, D., and Fahey, J. L. (1991) Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: Studies in patients with chronic progressive multiple sclerosis. Int. J. Immunopharmacol. 13, 455–461.

    Article  CAS  PubMed  Google Scholar 

  12. Yu, D. T., Clements, P. J., Peter, J. B., Levy, J., Paulus, H. E., and Barnett, E. V. (1974) Lymphocyte characteristics in rheumatic patients and the effect of azathioprine therapy. Arthritis Rheum. 17, 37–45.

    Article  Google Scholar 

  13. Tareyeva, I. E., Shilov, E. M., and Gordovskaya, N. B. (1980) The effects of azathioprine and prednisolone on T- and B-lymphocytes in patients with lupus nephritis and chronic glomerulonephritis. Clin. Nephrol. 14, 233–237.

    CAS  PubMed  Google Scholar 

  14. Salmaggi, A., Corsini, E., La Mantia, L., Dufour, A., Eoli, M., Milanese, C., and Nespolo, A. (1997) Immunological monitoring of azathioprine treatment in multiple sclerosis patients. J. Neurol. 244, 167–174.

    Article  CAS  PubMed  Google Scholar 

  15. Melms, A., Malcherek, G., Gern, U., Sommer, N., Weissert, R., Wietholter, H., and Buhring, H. J. (1993) Thymectomy and azathioprine have no effect on the phenotype of CD4 T lymphocyte subsets in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry. 56, 46–51.

    Article  CAS  PubMed  Google Scholar 

  16. Morimoto, C., Steinberg, A. D., Letvin, N. L., Hagan, M., Takeuchi, T., Daley, J., Levine, H., and Schlossman, S. F. (1987) A defect of immunoregulatory T cell subsets in systemic lupus erythematosus patients demonstrated with anti-2H4 antibody. J. Clin. Invest. 79, 762–768.

    Article  CAS  PubMed  Google Scholar 

  17. Chiorazzi, N., Fox, D. A., and Katz, D. H. (1976) Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. J. Immunol. 117, 1629–1637.

    CAS  PubMed  Google Scholar 

  18. Chiorazzi, N., Fox, D. A., and Katz, D. H. (1977) Hapten-specific IgE antibody responses in mice. VII. Conversion of IgE “non-responder” strains to IgE “responders” by elimination of suppressor T cell activity. J. Immunol. 118, 48–54.

    CAS  PubMed  Google Scholar 

  19. Duclos, H., Galanaud, P., Devinsky, O., Maillot, M. C., and Dormont, J. (1977) Enhancing effect of low dose cyclophosphamide treatment on the in vitro antibody response. Eur. J. Immunol. 7, 679–684.

    Article  CAS  PubMed  Google Scholar 

  20. Ferguson, R. M. and Simmons, R. L. (1978) Differential cyclophosphamide sensitivity of suppressor and cytotoxic cell precursors. Transplantation 25, 36–38.

    Article  CAS  PubMed  Google Scholar 

  21. Lagrange, P. H., Mackaness, G. B., and Miller, T. E. (1974) Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide. J. Exp. Med. 139, 1529–1539.

    Article  CAS  PubMed  Google Scholar 

  22. Noble, B., Parker, D., Scheper, R. J., and Turk, J. L. (1977) The relation between B-cell stimulation and delayed hypersensitivity: the effect of cyclophosphamide pretreatment on antibody production. Immunology 32, 885–891.

    CAS  PubMed  Google Scholar 

  23. Polak, L. and Turk, J. L. (1974) Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature 249, 654–656.

    Article  CAS  PubMed  Google Scholar 

  24. Rollinghoff, M., Starzinski-Powitz, A., Pfizenmaier, K. and Wagner, H. (1977) Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes. J. Exp. Med. 145, 455–459.

    Article  CAS  PubMed  Google Scholar 

  25. Sy, M. S., Miller, S. D., and Claman, H. N. (1977) Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J. Immunol. 119, 240–244.

    CAS  PubMed  Google Scholar 

  26. Aisenberg, A. C. (1973) Immunosuppression by alkylating agents-tolerance induction. Transplant Proc. 5 (3), 1221–1226.

    CAS  PubMed  Google Scholar 

  27. Berenbaum, M. C. (1963) Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 200, 84.

    Article  CAS  PubMed  Google Scholar 

  28. Cupps, T. R., Edgar, L. C., and Fauci, A. S. (1982) Suppression of human B lymphocyte function by cyclophosphamide. J. Immunol. 128, 2453–2457.

    CAS  PubMed  Google Scholar 

  29. Kawaguchi, S. (1970) Studies on the induction of immunological paralysis to bovine gamma-globulin in adult mice. II. The effect of cyclophosphamide. Immunology 19, 291–299.

    CAS  PubMed  Google Scholar 

  30. Many, A. and Schwartz, R. S. (1970) On the mechanism of immunological tolerance in cyclophosphamide-treated mice. Clin. Exp. Immunol. 6, 87–99.

    CAS  PubMed  Google Scholar 

  31. Santos, G. W. and Owens, A. H., Jr. (1966) 19S and 17S antibody production in the cyclophosphamide-or methotrexate-treated rat. Nature 209, 622–624.

    Google Scholar 

  32. Selgrade, M. K., Daniels, M. J., Hu, P. C., Miller, F. J., and Graham, J. A. (1982) Effects of immunosuppression with cyclophosphamide on acute murine cytomegalovirus infection and virus-augmented natural killer cell activity. Infect. Immun. 38, 1046–1055.

    CAS  PubMed  Google Scholar 

  33. Varkila, K. and Hurme, M. (1983) The effect of cyclophosphamide on cytotoxic T-lymphocyte responses: inhibition of helper T-cell induction in vitro. Immunology 48, 433–438.

    CAS  PubMed  Google Scholar 

  34. Walker, C. M., Paetkau, V., Rawls, W. E., and Rosenthal, K. L. (1985) Abrogation of antiPichinde virus cytotoxic T cell memory by cyclophosphamide and restoration by coinfection or interleukin 2. J. Immunol. 135, 1401–1407.

    CAS  PubMed  Google Scholar 

  35. Hurd, E. R. and Ziff, M. (1974) Parameters of improvement in patients with rheumatoid arthritis treated with cyclophosphamide. Arthritis Rheum. 17, 72–78.

    Article  CAS  PubMed  Google Scholar 

  36. North, R. J. (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 55, 1063–1074.

    Article  Google Scholar 

  37. Mokyr, M. B., Brundrett, R. B., Colvin, M., and Dray, S. (1986) Ability of cyclophosphamide in the absence of cross-linking activity to exert the immunomodulatory effect required for the cure of mice bearing a large MOPC-315 tumor. Cancer Res. 46, 3313–3320.

    CAS  PubMed  Google Scholar 

  38. Palermo, M. S., Giordano, M., and Olabuenaga, S., et al. (1985) Cyclophosphamide inhibits antibody-dependent cellular cytotoxicity (ADCC) suppression exerted by lymph node cells. Cell Immunol. 93, 438–446.

    Article  CAS  PubMed  Google Scholar 

  39. Wrone-Smith, T., Cankovic, M., VanBuren, E., and Lerman, S. (1993) Cyclophosphamide treatment of an SJL murine B-cell lymphoma increases the proportion of suppressive CD8+ over tumor-stimulatory CD4+ T-lymphocytes. Leukemia Res. 17 (11), 967–975.

    Article  CAS  Google Scholar 

  40. Tzai, T.-S., Huben, R. P., Zaleskis, G., Berleth, E. S., Ehrke, M. J., and Mihich, E. (1994) Effect of perioperative chemoimmunotherapy with cyclophosphamide and autologous tumor vaccine in murine MBT-2 bladder cancer. J. Urol. 151, 1680–1686.

    CAS  PubMed  Google Scholar 

  41. Tuttle, T. M., Fleming, M. D., Hogg, P. S., Inge, T. H., and Bear, H. D (1994) Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression. Ann. Surg. Onc. 1 (1), 53–58.

    Article  CAS  Google Scholar 

  42. Berd, D. and Mastrangelo, M. J. (1988) Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Res. 48, 1671–1675.

    CAS  PubMed  Google Scholar 

  43. Kuroi, K., Sato, Y., Yamaguchi, Y., and Toge, T. (1994) Modulation of suppressor cell activities by cyclophosphamide in breast cancer patients. J. Clin. Lab. Anal. 8, 123–127.

    Article  CAS  PubMed  Google Scholar 

  44. Yasunami, R. and Bach, J. F. (1988) Anti-suppressor effect of cyclophosphamide on the development of spontaneous diabetes in NOD mice. Eur. J. Immunol. 18, 481–484.

    Article  CAS  PubMed  Google Scholar 

  45. Bacelj, A., Charlton, B., and Mandel, T. E. (1989) Prevention of cyclophosphamide-induced diabetes by anti-V beta 8 T-lymphocyte-receptor monoclonal antibody therapy in NOD/ Wehi mice. Diabetes 38, 1492–1495.

    Article  CAS  PubMed  Google Scholar 

  46. Cailleau, C., Diu-Hercend, A., Ruuth, E., Westwood, R., and Carnaud, C. (1997) Treatment with neutralizing antibodies specific for IL-113 prevents cyclophosphamide-induced diabetes in nonobese diabetic mice. Diabetes 46, 937–940.

    Article  CAS  PubMed  Google Scholar 

  47. Takahashi, K., Satoh, J., Sagara, M., Zhu, X. P., Muto, G., Muto, Y., Fukuzawa, M., Nishimura, S., Miyaguchi, S., and Toyata, T. (1995) Analysis of action mechanism of lymphotoxin in prevention of cyclophosphamide-induced diabetes in NOD mice. J. Autoimmun. 8, 335–346.

    Article  CAS  PubMed  Google Scholar 

  48. Rothe, H., Faust, A., Schade, U., Kleemann, R., Bosse, G., Hibino, T., Martin, S., and Kolb, H. (1994) Cyclophosphamide treatment of female non-obese diabetic mice causes enhanced expression of inducible nitric oxide synthase and interferon-gamma, but not of interleukin-4. Diabetalogia 37, 1154–1158.

    Google Scholar 

  49. Mizuno, A., Iwami, T., Sano, T., Shi, K., Noma, Y., and Shima, K. (1993) Cyclophosphamide-induced diabetes in Long-Evans Tokushima lean rats: influence of ovariectomy on the development of diabetes. Metabolism 42 (7), 865–869.

    Article  CAS  PubMed  Google Scholar 

  50. Bersani-Amado, C. A., da S Duarte, A. J., Tanji, M. M., Cianga, M., and Jancar, S. (1990) Comparative study of adjuvant induced arthritis in susceptible and resistant strains of rats. III. Analysis of lymphocyte subpopulations. J. Rheumatol. 17, 153–158.

    CAS  PubMed  Google Scholar 

  51. Maguire, H.C. Jr. (1996) Cyclophosphamide and interleukin-12 synergistically upregulate the acquisition of allergic contact dermatitis in the mouse. Acta Derm. Venereol. 76, 277–279.

    PubMed  Google Scholar 

  52. Satoh, T., Chen, Q.-J., Sasaki, G., Yokozeki, H., Katayama, I., and Nishioka, K. (1997) Cyclophosphamide-induced blood and tissue eosinophilia in contact sensitivity: mechanism of hapten-induced eosinophil recruitment into the skin. Eur. J. Immunol. 27, 85–91.

    Article  CAS  PubMed  Google Scholar 

  53. Kamada, H., Takaoka, Y., Kitagaki, K., and Nagai, H. (1995) Effect of cyclophosphamide on lymphokine production in MRL/lpr.Yaa mice. Inflamm. Res. 44, 491–498.

    Article  CAS  PubMed  Google Scholar 

  54. Barrett, S. P., Toh, B.-H., Alderuccio, F., van Driel, I. R., and Gleeson, P. A. (1995) Organ-specific autoimmunity induced by adult thymectomy and cyclophosphamide-induced lymphopenia. Eur. J. Immunol. 25, 238–244.

    Article  CAS  PubMed  Google Scholar 

  55. Lehnert, S. and Rybka, W. B. (1994) Amplification of the graft-versus-host reaction by cyclophosphamide•dependence on timing of drug administration. Bone Marrow Transplantation 13, 463–477.

    Google Scholar 

  56. Fox, D. A., Millard, J. A., Treisman, J., Zeldes,W., Bergman, A., Depper, J., Dunne, R., and McCune, W. J. (1991) Defective CD2 pathway T cell activation in systemic lupus erythematosus. Arthritis Rheum. 34, 561–571.

    Google Scholar 

  57. Berenbaum, M.C. (1971) Is azathioprine a better immunosuppressive than 6-mercaptopurine? Clin. Exp. Immunol. 8, 1–8.

    CAS  PubMed  Google Scholar 

  58. Levy, J., Barnett, E. V., MacDonald, N. S., Klinenberg, J. R., and Pearson, C. M. (1972) The effect of azathioprine on gammaglobulin synthesis in man. J. Clin. Invest. 51, 2233–2238.

    Article  CAS  PubMed  Google Scholar 

  59. Dimitriu, A. and Fauci, A. S. (1978) Activation of human B lymphocytes. XI. Differential effects of azathioprine on B lymphocytes and lymphocyte subpopulations regulating B cell function. J. Immunol. 121, 2335–2339.

    CAS  PubMed  Google Scholar 

  60. Gorski, A., Korczak-Kowalska, G., Nowaczyk, M., Paczek, L., and Gaciong, Z. (1983) The effect of azathioprine on terminal differentiation of human B lymphocytes. Immunopharmacology 6, 259–266.

    Article  CAS  PubMed  Google Scholar 

  61. Swanson, M. A. and Schwartz, R. S. (1967) Immunosuppressive therapy. The relation between clinical response and immunologic competence. N. Engl. J. Med. 277, 163–170.

    Article  CAS  PubMed  Google Scholar 

  62. Urowitz, M. B., Smythe, H. A., Able, T., Norman, C. S., and Travis, C. (1982) Long-term effects of azathioprine in rheumatoid arthritis. Ann. Rheum. Dis. 41 (Suppl 1), 18–22.

    Article  PubMed  Google Scholar 

  63. Bach, M. A. and Bach, J. F. (1972) Activities of immunosuppressive agents in vitro. II. Different timing of azathioprine and methotrexate in inhibition and stimulation of mixed lymphocyte reaction. Clin. Exp. Immunol. 11, 89–98.

    CAS  PubMed  Google Scholar 

  64. Brown, T. E., Ahmed, A., Filo, R. S., Knudsen, R. C., and Sell, K. W. (1976) The immunosuppressive mechanism of azathioprine. I. In vitro effect on lymphocyte function in the baboon. Transplantation 21, 27–35.

    Google Scholar 

  65. Al-Safi, S. A. and Maddocks, J. L. (1983) Effects of azathioprine on the human mixed lymphocyte reaction (MLR). Br. J. Clin. Pharmacol. 15, 203–209.

    Article  CAS  PubMed  Google Scholar 

  66. Ivanyi, L. (1979) The effects of azathioprine and levamisole on lymphocyte stimulation. Clin. Exp. Immunol. 38, 370–375.

    CAS  PubMed  Google Scholar 

  67. Mansour, A. and Nelson, D. S. (1979) Effect of treatment with azathioprine on the responses of rat lymphocytes to phytohaemagglutinin. Aust. J. Exp. Biol. Med. Sci. 57, 115–125.

    Article  CAS  PubMed  Google Scholar 

  68. Cook, J. D., Lai, W., and McGrane, B. (1983) The effect of suboptimal concentrations of mitogens on the immunosuppressive action of azathioprine and prednisolone on human lymphocytes in vitro. J. Immunopharmacol. 1983 (5), 257–275.

    Google Scholar 

  69. Dayton, J. S., Turka, L. A., Thompson, C. B., and Mitchell, B. S. (1992) Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T lymphocyte proliferation and purine ribonucleotide metabolism. Mol. Pharmacol. 41, 671–676.

    CAS  PubMed  Google Scholar 

  70. Purves, E. C. and Berenbaum, M. C. (1975) Selective suppression of murine antibody-dependent cell-mediated cytotoxicity by azathioprine. Transplantation 19, 274–276.

    Article  CAS  PubMed  Google Scholar 

  71. Shih, W. W., Ellison, G. W., Myers, L. W., Durkos-Smith, D., and Fahey, J. L. (1982) Locus of selective depression of human natural killer cells by azathioprine. Clin. Immunol. Immunopathol. 23, 672–681.

    Article  CAS  PubMed  Google Scholar 

  72. Prince, H. E., Ettenger, R. B., Dorey, F. J., Fine, R. N., and Fahey, J. L. (1984) Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. J. Clin. Immunol. 4, 312–318.

    Article  CAS  PubMed  Google Scholar 

  73. Abom, B. and Pedersen, B. K. (1987) The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 5, 47–52.

    CAS  PubMed  Google Scholar 

  74. Anaclerio, A., Conti, G., Goggi, G., Honorati, M. C., Ruggeri, A., Moras, M. L., and Spreafico, F. (1979) Effect of cytotoxic agents on suppressor cells in mice. Eur. J. Cancer 16, 53–58.

    Google Scholar 

  75. Duclos, H., Maillot, M. C., and Galanaud, P. (1982) Differential effects of azathioprine on T cells regulating murine B-cell function. Immunology 46, 595–601.

    CAS  PubMed  Google Scholar 

  76. Medzihradsky, J. L., Hollowell, R. P., and Elion, G. B. (1981) Differential inhibition by azathioprine and 6-mercaptopurine of specific suppressor T cell generation in mice. J. Immunopharmacol. 3, 1–16.

    CAS  PubMed  Google Scholar 

  77. Shand, F. L. and Howard, J. G. (1978) Cyclophosphamide inhibited B cell receptor regeneration as a basis for drug-induced tolerance. Nature 271, 255–257.

    Article  CAS  PubMed  Google Scholar 

  78. Tabi, Z., Allan, J. E., Ceredig, R., and Doherty, P. C. (1988) Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells. Immunology 63, 423–429.

    CAS  PubMed  Google Scholar 

  79. Poulter, L. W., Bradley, N. J., and Turk, J. L. (1974) Differential effect of azathioprine on theta-antigenicity of mouse lymphocytes. Immunology 26, 777–785.

    CAS  PubMed  Google Scholar 

  80. Bach, J. F. and Dardenne, M. (1971) Activities of immunosuppressive agents in vitro. I. Rosette inhibition by azathioprine. Rev. Eur. Etudes Clin. Biol. 16, 770–777.

    CAS  Google Scholar 

  81. Bach, J. F. and Dardenne, M. (1972) Antigen recognition by T lymphocytes. II. Similar effects of azathioprine, antilymphocyte serum, and anti-theta serum on rosette-forming lymphocytes in normal and neonatally thymectomized mice. Cell. Immunol. 3, 11–21.

    Article  CAS  PubMed  Google Scholar 

  82. Verhaegen, H., De Cock, W., and De Cree, J. (1977) The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients. Clin. Exp. Immunol. 29, 311–315.

    CAS  PubMed  Google Scholar 

  83. Pallister, C. J. and Warnock, D. W. (1989) Effect of antimicrobial and antineoplastic drugs alone and in combination on the phagocytic and candidacidal function of human polymorphonuclear leukocytes. J. Antimicrob. Chemother. 23, 87–94.

    Article  CAS  PubMed  Google Scholar 

  84. Altankov, G., Marinova-Mutafchieva, L., Nikolaeva, N., and Penkova, R. (1991) Changes in the adhesive phenotype of regional lymphocytes in rats with adjuvant arthritis: alteration by cyclophosphamide. Meth Find Exp. Clin. Pharmacol. 13 (4), 263–268.

    CAS  Google Scholar 

  85. Cronstein, B. N. (1996) Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum. 39 (12), 1951–1960.

    Article  CAS  PubMed  Google Scholar 

  86. Weinblatt, M. E., Coblyn, J. S., Fox, D. A., Fraser, P. A., Holdsworth, D. E., Glass, D. N., and Trentham, D. E. (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312, 818–822.

    Article  CAS  PubMed  Google Scholar 

  87. Gadeberg, O. V., Rhodes, J. M., and Larsen, S. O. (1975) The effect of various immunosuppressive agents on mouse peritoneal macrophages and on the in vitro phagocytosis of Escherichia coli O4:K3:H5 and degradation of 125I-labelled HSA-antibody complexes by these cells. Immunology 28, 59–70.

    CAS  PubMed  Google Scholar 

  88. Giordano, M., Geffner, J. R., Prat, A., Palermo, M. S., Serebrinsky, G. P., and Isturiz, M. A. (1988) Cyclophosphamide modulates arachidonic acid metabolism by peritoneal macrophages. Int. J. Immunopharmacol. 10, 939–944.

    Article  CAS  PubMed  Google Scholar 

  89. Arinoviche, R. and Loewi, G. (1979) Comparison of the effects of two cytotoxic drugs and of antilymphocytic serum on immune and non-immune inflammation in experimental animals. Ann. Rheum. Dis. 29, 32–39.

    Article  Google Scholar 

  90. Gotjamanos, T. (1971) The effect of azathioprine on phagocytic activity and morphology of reticulo-endothelial organs in mice. Pathology 3, 171–179.

    CAS  PubMed  Google Scholar 

  91. Norris, D. A., Weston, W. L., and Sams, W. M., Jr. (1977) The effect of immunosuppressive and anti-inflammatory drugs on monocyte function in vitro. J. Lab. Clin. Med. 90, 569–580.

    CAS  PubMed  Google Scholar 

  92. Naveh, N., Weissman, C., and Dottan, S. A. (1988) Azathioprine’s inhibitory effect on prostaglandin E2 production is not via cyclooxygenase inhibition. Biochem. Biophys. Res. Commun. 157, 727–732.

    Article  CAS  PubMed  Google Scholar 

  93. Homo-Delarche, F., Bach, J. F., and Dardenne, M. (1988) In vitro inhibition of prostaglandin production by azathioprine and 6-mercaptopurine. Prostaglandins 35, 479–491.

    Article  CAS  PubMed  Google Scholar 

  94. Murthy, S. N., Anania, T., and Clearfield, H. R. (1991) Azathioprine reduces extravasation and neutrophil trafficking in immune complex-mediated inflammation in the rat colon. Agents Actions 34, 244–246.

    Article  CAS  PubMed  Google Scholar 

  95. Elion, G. B. (1986) The pharmacology of azathioprine. Ann. N YAcad Sci. 33, 401–407.

    Google Scholar 

  96. Liu, H.-N. and Wong, C.-K. (1997) In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Arch. Dermatol. Res. 289, 94–97.

    Article  CAS  PubMed  Google Scholar 

  97. Multhoff, G., Meier, T., Botzler, C., Wiesnet, M., Allenbacher, A., Wilmanns, W., and Issels, R. D. (1985) Differential effects of ifosfamide on the capacity of cytotoxic T lymphocytes and natural killer cells to lyse their target cells correlate with intracellular glutathione levels. Blood 85 (8), 2124–2131.

    Google Scholar 

  98. Botzler, C., Kis, K., Issels, R., and Multhoff, G. (1997) A comparison of the effects of ifosfamide vs. mafosfamide treatment on intracellular glutathione levels and immunological functions of immunocompetent lymphocyte subsets. Exp. Hematol. 25, 338–344.

    CAS  PubMed  Google Scholar 

  99. Wilmer, J. L., Erexson, G. L., and Kligerman, A. D. (1990) Effect of acrolein on phosphoramide mustard-induced sister chromatid exchanges in cultured human lymphocytes. Cancer Res. 50, 4635–4638.

    CAS  PubMed  Google Scholar 

  100. Pette, M., Gold, R., Pette, D. F., Hartung, H.-P., and Toyka, K. V. (1995) Malfosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes: a possible mechanism of its immunosuppressive action. Immunopharmacology 30, 59–69.

    Article  CAS  PubMed  Google Scholar 

  101. da Silva, C. P., de Oliveira, C. R., and de Lima, M. P. (1996) Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol. 51, 1331–1340.

    Article  PubMed  Google Scholar 

  102. Hemendinger, R. A. and Bloom, S. E. (1996) Selective mitomycin C and cyclophosphamide induction of apoptosis in differentiating B lymphocytes compared to T lymphocytes in vivo. Immunopharmacology 35, 71–82.

    Article  CAS  PubMed  Google Scholar 

  103. Hortelano, S. and Bosca, L. (1997) 6-mercaptopurine decreases the Bcl-2/Bax ratio and induces apoptosis in activated splenic B lymphocytes. Mol. Pharmacol. 51, 414–421.

    Google Scholar 

  104. Colucci, F., Cilio, C. M., Lejon, K., Goncalves, C. P., Bergman, M.-L., and Holmberg, D. (1996) Programmed cell death in the pathogenesis of murine IDDM: resistance to apoptosis induced in lymphocytes by cyclophosphamide. J. Autoimmun. 9, 271–276.

    Article  CAS  PubMed  Google Scholar 

  105. Danao, T. and Segal, A. M. (1990) Pulsed suppressive treatment in rheumatoid arthritis: intravenous methylprednisolone and nitrogen mustard. J. Rheumatol. 17, 893–899.

    CAS  PubMed  Google Scholar 

  106. Cooperating Clinics Committee of the American Rheumatism Association (1970) A controlled trial of cyclophosphamide in rheumatoid arthritis. New Engl. J. Med. 283 (17), 883–889.

    Google Scholar 

  107. Lidsky, M. D., Sharp, J. T., and Billings, S. (1973) Double-blind study of cyclophosphamide in rheumatoid arthritis. Arthritis Rheum. 16, 148–153.

    Article  CAS  PubMed  Google Scholar 

  108. Arnold, M. H., Janssen, B., Schrieber, L., and Brooks, P. M. (1989) Prospective pilot study of intravenous pulse cyclophosphamide therapy for refractory rheumatoid arthritis. Arthritis Rheum. 32, 933–934 (letter).

    Google Scholar 

  109. Le Thi Huong, D., Papo, T., Piette, J. C., Wechsler, B., Bletry, O., Lamas, G., Baumelou, A., Le Hoang, P., Pennaforte, J.-L., Valcke, J.-C. and Godeau, P. (1996) Monthly intravenous pulse cyclophosphamide therapy in Wegener’s granulomatosis. Clin. Exp. Rheumatol. 14, 9–16.

    Google Scholar 

  110. Fauci, A. S., Haynes, B. F., Katz, P., and Wolff, S. M. (1983) Wegener’s granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med. 98, 76–85.

    Article  CAS  PubMed  Google Scholar 

  111. Hoffman, G. S., Leavitt, R. Y., Fleisher, T. A., Minor, J. R., and Fauci, A. S. (1990) Treatment of Wegener’s granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am. J. Med. 89, 403–410.

    Article  CAS  PubMed  Google Scholar 

  112. Alexopoulos, E., Sakellariou, G., Memmos, D., Karamitsos, K., Leontsini, M., and Papadimitriou, M. (1993) Cyclophosphamide provides no additional benefit to steroid therapy in the treatment of idiopathic membranous nephropathy. Am. J. Kidney Dis. 21, 497–503.

    CAS  PubMed  Google Scholar 

  113. Falk, R. J., Hogan, S. L., Muller, K. E., and Jennette, J. C. (1992) Treatment of progressive membranous glomerulopathy: a randomized trial comparing cyclophosphamide and corticosteroids with corticosteroids alone. The Glomerular Disease Collaborative Network. Ann. Intern. Med. 116, 438–445.

    Article  CAS  PubMed  Google Scholar 

  114. Ponticelli, C., Zucchelli, P., Passerini, P., Cagnoli, L., Cesana, B., Pozzi, C., Pasquali, S., Imbasciati, E., Grassi, C., Redaelli, B., Sasdelli, M., and Locatelli, F. (1989) A randomized trial of methylprednisone and chlorambucil in idiopathic membranous nephropathy. N. Engl. J. Med. 320, 8–13.

    Article  CAS  PubMed  Google Scholar 

  115. Fries, J. F., Sharp, G. C., McDevitt, H. O., and Holman, H. R. (1973) Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis. Arthritis Rheum. 16 (2), 154–162.

    Article  CAS  PubMed  Google Scholar 

  116. Austin, H. A. I., Klippel, J. H., Balow, J. E., LeRiche, N. G., Steinberg, A. D., Plotz, P. H., and Decker, J. L. (1986) Therapy of lupus nephritis: A controlled trial of prednisone and cytotoxic drugs. N. Engl. J. Med. 314, 614–619.

    Article  PubMed  Google Scholar 

  117. Steinberg, A. D. and Steinberg, S. C. (1991) Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 34, 945–950.

    Article  CAS  PubMed  Google Scholar 

  118. Chan, T. M., Li, F. K., Wong, R. W. S., Chan, K. W., and Cheng, I. K. P. (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisone followed by azathioprine and prednisolone. Nephron 71, 321–327.

    Article  CAS  PubMed  Google Scholar 

  119. Dooley, M. A., Hogan, S., Jennette, C., and Falk, R. (1997) Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 51 (4), 1188–1195.

    Article  CAS  PubMed  Google Scholar 

  120. Boumpas, D. T., Austin, H. A., Vaughn, E. M., Klippel, J. H., Steinberg, A. D., Yarboro, C. H., and Balow, J. E. (1992) Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340, 741–745.

    Article  CAS  PubMed  Google Scholar 

  121. McCune, W. J., Dunne, R. B., Millard, J., Gilson, B. J., and Fox, D. A. (1990) Two year follow-up of patients with severe systemic lupus (SLE) treated with pulse cyclophosphamide. Arthritis Rheum. 33 (Suppl), S103.

    Google Scholar 

  122. Strober, S., Farinas, M. C., Field, E. H., Solovera, J. J., Kiberd, B. A., Myers B. D., and Hoppe, R. T. (1988) Treatment of lupus nephritis with total lymphoid irradiation: observations during a 12–79-month followup. Arthritis Rheum. 31, 850–858.

    Article  CAS  PubMed  Google Scholar 

  123. Chandhoke, M. K., Johnson, R., Bnat, S., Morgan, L., and McCune, W. J. (1996) Outcome of intravenous pulse cyclophosphamide therapy (IVCTX) of class V lupus nephritis: relationship to electron microscopic scoring of membranous changes. Arthritis Rheum. 39 (9), S225.

    Google Scholar 

  124. Boumpas, D. T., Yamada, H., Patronas, N. J., Scott, D., Klippel, J. H., and Balow, J. E. (1991) Pulse cyclophosphamide for severe neuropsychiatric lupus. Q. J. Med. 81 (296), 975–984.

    Article  CAS  PubMed  Google Scholar 

  125. Neuwelt, C. M., Lacks, S., Kaye, B. R., Ellman, J. B., and Boroenstein, D. G. (1995) Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med. 98, 32–46.

    Article  CAS  PubMed  Google Scholar 

  126. Barile, L. and Lavalle, C. (1992) Transverse myelitis in systemic lupus erythematosus—the effect of IV pulse methylprednisolone and cyclophosphamide. J. Rheumatol. 19, 370–372.

    CAS  PubMed  Google Scholar 

  127. Fukuda, M., Kamiyama, Y., Kawahara, K., Kawamura, K., Mori, T., and Honda, M. (1994) The favourable effect of cyclophosphamide pulse therapy in the treatment of massive pulmonary haemorrhage in systemic lupus erythematosus. J. Pediatr. 153, 167–170.

    CAS  Google Scholar 

  128. Boulware, D. W. and Makkena, R. (1991) Monthly cyclophosphamide in lupus pneumonitis and myositis J. Rheumatol. 18, 153 (abstract).

    CAS  PubMed  Google Scholar 

  129. Eiser, A. R. and Shanies, H. M. (1994) Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum. 37, 428–431.

    Article  CAS  PubMed  Google Scholar 

  130. Boumpas, D. T., Barez, S., and Klippel, J. H. (1990) Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann. Intern. Med. 112, 674.

    Article  CAS  PubMed  Google Scholar 

  131. Laing, T. J. (1988) Gastrointestinal vasculitis and pneumatosis intestinalis due to systemic lupus erythematosus: successful treatment with pulse intravenous cyclophosphamide. Amer. J. Med. 85, 555–558.

    Article  CAS  PubMed  Google Scholar 

  132. Roach, B. A. and Hutchinson, G. J. (1993) Treatment of refractory, systemic lupus erythematosus-associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide. Arthritis Rheum. 36, 682–684.

    Article  CAS  PubMed  Google Scholar 

  133. Balow, J. E., Austin, H. A., Tsokos, G. C., Antonovych, T. T., Steinberg, A. D., and Klippel, J. H. (1987) NIH conference: lupus nephritis. Ann. Intern. Med. 106, 79–94.

    Article  CAS  PubMed  Google Scholar 

  134. Garancis, J. C. and Piering, W. F. (1973) Prolonged cyclophosphamide or azathioprine therapy of lupus nephritis. Clin. Pharmacol. Ther. 14, 130 (abstract).

    Google Scholar 

  135. Donadio, J. V., Holley, K. E., Ferguson, R. H., and Ilstrup, D. M. (1976) Progressive lupus glomerulonephritis: treatment with prednisone and combined prednisone and cyclophosphamide. Mayo Clin. Proc. 51, 484–494.

    PubMed  Google Scholar 

  136. Donadio, J. V. J., Holley, K. E., Ferguson, R. H., and Ilstrup, D. M. (1978) Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide N. Engl. J. Med. 299, 1151–1155.

    Article  PubMed  Google Scholar 

  137. Donadio, J. V. J. and Glassock, R. J. (1993) Immunosuppressive drug therapy in lupus nephritis: in-depth review. Am. J. Kidney Dis. 21 (3), 239–250.

    PubMed  Google Scholar 

  138. Euler, H. H., Schroeder, J. O., Harten, P., Zeuner, R. A., and Gutschmidt, H. J. (1994) Treatment-free remission in severe systemic lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. Arthritis Rheum. 37, 1784–1794.

    Article  CAS  PubMed  Google Scholar 

  139. Schroeder, J. O., Schwab, U., Zeuner, R., Fastenrath, S., and Euler, H. (1997) Plasmapheresis and subsequent pulse cyclophosphamide in severe systemic lupus erythematosus: preliminary results of the LPSG trail. Arthritis Rheum. 40, 325.

    Google Scholar 

  140. Talar-Williams, C., Hijazi, Y. M., Walther, M. M., Linehan, W. M., Hallahan, C. W., Lubensky, I., Kerr, G. S., Hoffman, G. S., Fauci, A. S., and Sneller, M. C. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener’s granulomatosis. Ann. Intern. Med 124, 477–484.

    Article  CAS  PubMed  Google Scholar 

  141. Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E. J., Van Leeuwen, F. E., Lynch, C. F., Hagenbeek, A., Stovall, M., Banks, P. M., and Adami, J. (1995) Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma. J. Natl. Cancer Inst. 87, 524–530.

    Article  CAS  PubMed  Google Scholar 

  142. Baker, G. L., Kahl, L. E., Zee, B. C., Stolzer, B. L., Agarwal, A. K., and Medsger, T. A., Jr. (1987) Malignancy following treatment of rheumatoid arthritis with cyclophosphamide Am. J. Med. 83, 1–9.

    Article  CAS  PubMed  Google Scholar 

  143. Hoffman, G. S., Kerr, G. S., Leavitt, R. Y., Hallahan, C. W., Lebovics, R. S., Travis, W. D., Rottem, M., and Fauci, A. S. (1992) Wegener’s granulomatosis: an analysis of 158 patients. Ann. Intern. Med. 116, 488–498.

    Article  CAS  PubMed  Google Scholar 

  144. Radis, C. D., Kahl, L. E., Baker, G. L., Wasko, M. C., Cash, J. M., Gallatin, A. (1995) B.L. Stolzer, A.K. Agarwal, T.A. Medsger and C.K. Kwoh, Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. Arthritis Rheum. 38, 1120–1127.

    Article  CAS  PubMed  Google Scholar 

  145. Stillwell, T. J., Benson, R. C., Jr., DeRemee, R. A., McDonald, T. J., and Weiland, L. H. (1988) Cyclophosphamide-induced bladder toxicity in Wegener’s granulomatosis. Arthritis Rheum. 31, 465–470.

    Article  CAS  PubMed  Google Scholar 

  146. Plotz, P. H., Klippel, J. H., Decker, J. L., Grauman, D., Wolff, B., Brown, B. C., and Rutt, G. (1979) Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann. Intern. Med. 91, 221–223.

    Article  CAS  PubMed  Google Scholar 

  147. Pedersen-Bjergaard, J., Ersboll, J., Hansen, V. L., Sorensen, B. L., Christofferson, K., Hou-Jensen, K., Nissen, N. I., Knudsen, J. B., Hansen, M. M. (1988) Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin’s lymphoma. N. Engl. J. Med. 318, 1028–1032.

    Article  CAS  PubMed  Google Scholar 

  148. Gmelig-Meyling, F., Dawisha, S., and Steinberg, A. D. (1992) Assessment of in vivo frequency of mutated T cells in patients with systemic lupus erythematosus. J. Exp. Med. 175, 297–300.

    Article  CAS  PubMed  Google Scholar 

  149. Baltus, J. A. M., Boersma, J. W., Hartman, A. P., and Vandenbroucke, J. P. (1983) The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann. Rheum. Dis. 368–373.

    Google Scholar 

  150. Schneider, V., Kay, S., and Lee, H. M. (1983) Immunosuppression as a high-risk factor in the development of condyloma acuminatum and squamous neoplasia of the cervix. Acta Cytolog. 27, 220–224.

    CAS  Google Scholar 

  151. Ognenowski, V., Farrehi, J., Selvaggi, S. M., and McCune, W. J. (1996) Increased cervical atypia in women with systemic lupus erythematosus treated with intravenous pulse cyclophosphamide. Arthritis Rheum. 39, S213.

    Google Scholar 

  152. McCarthy, C. J., Sheldon, S., Ross, C. W., and McCune, W. J. (1998) Cytogenetic abnormalities and therapy-related myelodysplastic syndromes in rheumatic disease. Arthritis Rheum. 41, 1493–1496.

    Article  CAS  PubMed  Google Scholar 

  153. Snyder, L. S. and Anderson, M. L. (1993) Cyclophosphamide-induced hepatotoxicity in a patient with Wegener’s granulomatosis. Mayo Clin. Proc. 68, 1203–1204.

    Article  CAS  PubMed  Google Scholar 

  154. Diaz-Gonzalez, F., Casteneda-Sanz, S., Lopez-Robledillo, J. C., and Garcia-Vicuna, R. (1992) Letter: lung fibrosis in a patient with polyarteritis nodosa receiving cyclophosphamide therapy. J. Rheumatol. 19, 325–327.

    CAS  PubMed  Google Scholar 

  155. Stentoft, J. (1987) Progressive pulmonary fibrosis complicating cyclophosphamide therapy. Acta Med. Scand. 221, 403–407.

    Article  CAS  PubMed  Google Scholar 

  156. Morse, C. C., Sigler, C., Lock, S., Hakkinen, P. J., Haschek, W. M., and Witschi, H. P. (1985) Pulmonary toxicity of cyclophosphamide: a 1-year study. Exp. Mol. Pathol. 42, 251–260.

    Article  CAS  PubMed  Google Scholar 

  157. USui, Y., Aida,.H., Kimula, Y., Miura, H., Aoyagi, Y., Nakayama, M., and Takayama, S. (1992) A case of cyclophosphamide-induced interstitial pneumonitis diagnosed by bronchoalveolar lavage. Respiration 59, 125–128.

    CAS  Google Scholar 

  158. Lynch, J. P. I. and Hunninghake, G. W. (1992) Pulmonary complications of collagen vascular disease. Annu. Rev. Med. 43, 17–35.

    Article  PubMed  Google Scholar 

  159. Gardner, S. F., Lazarus, H. M., Bednarczyk, E. M., Creger, R. J., Miraldi, F. D., Leisure, G., and Green, J. A. (1993) High-dose cyclophosphamide-induced myocardial damage during BMT: assessment by positron emission tomography. Bone Marrow Transplant 12, 139–144.

    CAS  PubMed  Google Scholar 

  160. Dow, E., Schulman, H., and Agura, E. (1993) Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 12, 169–172.

    CAS  PubMed  Google Scholar 

  161. Gilchrist, D. M. and Friedman, J. M. (1989) Teratogenesis and IV cyclophosphamide J. Rheumatol. 16, 1008–1009 (letter).

    Google Scholar 

  162. Kirshon, B., Wasserstrum, N., and Willis, R. (1988) Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet. Gynecol. 72, 462.

    CAS  PubMed  Google Scholar 

  163. Bermas, B. L. and Hill, J. A. (1995) Effects of immunosuppressive drugs during pregnancy. Arthritis Rheum. 38, 1722–1732.

    Article  CAS  PubMed  Google Scholar 

  164. Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T., and Aoki, Y. (1977) Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39, 1403–1409.

    Article  CAS  PubMed  Google Scholar 

  165. Boumpas, D. T., Austin, I.,H. A., Vaughan, E. M., Yarboro, C. H., Klippel, J. H., and Balow, J. E (1993) Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Int. Med. 119, 366–369.

    CAS  Google Scholar 

  166. Wallace, D. J., Podell, T. E., and Weiner, J. M., et al (1982) Lupus nephritis: Experience with 230 patients in a private practice from 1950 to 1980. Am. J. Med. 72, 209.

    Article  CAS  PubMed  Google Scholar 

  167. Dillard, M. G., Dujovne, I., Pollak, V. E., and Pirani, C. I. (1973) The effect of treatment with prednisone and nitrogen mustard on the renal lesions and life span of patients with lupus glomerulonephritis. Nephron 10, 273–291.

    Article  CAS  PubMed  Google Scholar 

  168. Wallace, D. J. and Metzger, A. L. (1995) Successful use of nitrogen mustard for cyclophosphamide resistant diffuse proliferative lupus glomerulonephritis: report of 2 cases. J. Rheum. 22(4), 801, 802.

    Google Scholar 

  169. Vonderheid, E. C., Tan, E. T„ Kantor, A. F., Shrager, L., Micdily, B., and Van Scott, E. J. (1995) Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J. Am. Acad. Dermatol. 20, 416–428.

    Google Scholar 

  170. Snaith, M. I., Holt, J. M., Oliver, D. O., Dunnill, M. S., Halley, W., and Stephenson, A. C. ((1973) Treatment of patients with systemic lupus erythematosus including nephritis with chlorambucil. Br. Med. J. 2, 197–201.

    Google Scholar 

  171. Epstein, W. V. and Grausz, H. (1974) Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum. 17, 129–142.

    Article  CAS  PubMed  Google Scholar 

  172. Sabbour, M. S. and Osman, L. M. (1979) Comparison of chlorambucil, azathioprine or cyclophosphamide combined with corticosteroids in the treatment of lupus nephritis. Br. J. Dermatol. 100 (2), 113–125.

    Article  CAS  PubMed  Google Scholar 

  173. Kataria, Y. P. (1980) Choorambucil in sarcoidosis. Chest 78, 36–43.

    Article  CAS  PubMed  Google Scholar 

  174. Chiappelli, F., Myers, L. W., Ellison, G. W., Liao, D., and Fahey, J. L. (1991) Preferential reductions in lymphocyte sub-populations induced by monthly pulses of chlorambucil: studies in patients with chronic progressive multiple sclerosis. Int. J. Immunopharmacol. 13, 455–461.

    Article  CAS  PubMed  Google Scholar 

  175. Patapanian, H., Graham, S., Sambrook, P. N., Brown, C. D., Champion, G. D., Cohen, M. L., and Day, R. O. (1988) The oncogenicity of chlorambucil in rheumatoid arthritis. Br. J. Rheumatol. 27, 44–47.

    Article  CAS  PubMed  Google Scholar 

  176. Cade, R., Spooner, G., Schlein, E., Pickering, M., DeQuesada, A., Holcomb, A. Juncos, L., Richard, G., Shires, D., Levin, D., Hackett, R., Free, J., Hunt, R., and Fregly, M. (1973) Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis. Nephron 10, 37–56.

    CAS  PubMed  Google Scholar 

  177. Esdaile, J. M., Joseph, L., Mackenzie, T., Kashgarian, M., and Hayslett, J. P. (1993) The pathogenesis and prognosis of lupus nephritis: information from repeat renal biopsy. Semin. Arthritis Rheum. 23, 135–148.

    Article  CAS  PubMed  Google Scholar 

  178. Esdaile, J. M., Abrahamowicz, M., Mackenzie, T., Hayslett, J. P., and Kashgarian, M. (1994) The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum. 37, 359–368.

    Article  CAS  PubMed  Google Scholar 

  179. Esdaile, J. M., Joseph, L., Mackenzie, T., Kashgarian, M., and Hayslett, J. P. (1994) The benefit of early treatment with immunosuppressive agents in lupus nephritis J. Rheumatol. 21, 2046–2051 (see comments).

    Google Scholar 

  180. Kerstens, P. J. S. M., Stolk, J. N., De Abreu, R. A., Lambooy, L. H. J., van de Putte, L. B. A., and Boeerbooms, A. A. M. T. (1995) Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum. 38, 142–145.

    Article  CAS  PubMed  Google Scholar 

  181. Kinlen, L. J. (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am. J. Med. 78, 44–49.

    Article  CAS  PubMed  Google Scholar 

  182. Silman, A. J., Petri, J., Hazleman, B., and Evans, S. J. W. (1988) Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20-year follow-up study. Ann. Rheum. Dis. 47, 988–992.

    Google Scholar 

  183. Tage-Jensen, U., Schlichting, T., Thomsen, H. F., and Thomsen, C. (1987) Malignancies following long-term azathioprine treatment in chronic liver disease. Liver 7, 81–83.

    CAS  PubMed  Google Scholar 

  184. Wilkinson, A. H., Smith, J. L., Hunsicker, L. G. Tobacman, J., Kapelanski, D. P., Johnson, M., Wright, F. H., Behrendt, D. M., and Corry, R. J. (1989) Increased frequency of post-transplant lymphomas in patients treated with cyclosporin, azathioprine, and prednisone. Transplantation 47, 293–296.

    Google Scholar 

  185. Kinlen, L. J. (1992) Malignancy in autoimmune diseases. Autoimmunity 5, 363–371.

    Google Scholar 

  186. Bottomley, W. W., Ford, G., Cunliffe, W. J., and Cotterill, J. A. (1995) Aggressive squamous cell carcinomas developing in patients receiving long-term azathioprine. Br. J. Dermatol. 133, 460–462.

    Article  CAS  PubMed  Google Scholar 

  187. Balachandran, I. and Galagan, K. S. (1984) Cervical carcinoma in situ associated with azathioprine therapy: a case report and literature review. Acta Cytologica 28, 699–702.

    CAS  PubMed  Google Scholar 

  188. Rothenberg, R. J., Graziano, F. M., Grandone, J. T., Goldberg, J. W., Bjarnason, D. F., and Finesilver, A. G. (1988) The use of methotrexate in steroid-resistant systemic lupus erythematosus. Arthritis Rheum. 31 (5), 612–615.

    Article  CAS  PubMed  Google Scholar 

  189. Wilke, W. S., Krall, P.L., Scheetz, R. J., Babiak, T., Danao, T., Mazanec, D. J., Segal, A. M., and Clough, J. D. (1991) Methotrexate for systemic lupus erythematosus: a retrospective analysis of 17 unselected cases. Clin. Exp. Rheumatol. 9, 581–587.

    CAS  PubMed  Google Scholar 

  190. Wilson, K. and Abeles, M. (1994) A 2 year, open ended trial of methotrexate in systemic lupus erythematosus. J. Rheumatol. 21 (9), 1674–1677.

    CAS  PubMed  Google Scholar 

  191. Walz LeBlanc, B. A., Dagenais, P., Urowitz, M. B., and Gladman, D. D. (1994) Methotrexate in systemic lupus erythematosus. J. Rheumatol. 21, 836–838.

    Google Scholar 

  192. Gausauge, S., Breitbart, A., Rinardi, N., and Schwartz-Eywill, M. (1997) Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann. Rheum. Dis. 55, 332–335.

    Google Scholar 

  193. Tugwell, P., Bennett, K., and Gent, M. (1987) Methotrexate in rheumatoid arthritis: indications, contraindications, efficacy, and safety. Ann. Intern. Med. 107, 358–366.

    Article  CAS  PubMed  Google Scholar 

  194. Weinblatt, M. E. (1995) Methotrexate for chronic diseases in adults. N. Engl. J. Med. 332, 330–331.

    Article  CAS  PubMed  Google Scholar 

  195. Dubois, E. L. (1956) Systemic lupus erythematosus: recent advances in its diagnosis and treatment. Ann. Intern. Med. 45, 163–184.

    Article  CAS  PubMed  Google Scholar 

  196. Garancis, J. C. and Piering, W. F. (1973) Prolonged cyclophosphamide or azathioprine therapy of lupus nephritis. Clin. Pharmacol. Ther. 14, 130 (abstract).

    Google Scholar 

  197. Ginzler, E., Diamond, H., Guttadauria, M., and Kaplan, D. (1976) Prednisone and azathioprine compared to prednisone plus low dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum. 19, 693–699.

    Article  CAS  PubMed  Google Scholar 

  198. Marmont, A. M. (1980) Systemic Lupus Erythematosus L. Pozzi, Rome (in Italian).

    Google Scholar 

  199. Sessoms, S. L. and Kovarsky, J. (1984) Monthly intravenous cyclophosphamide in the treatment of severe systemic lupus erythematosus. Clin. Exp. Rheumatol. 2, 247–251.

    CAS  PubMed  Google Scholar 

  200. Lehman, T. J., Sherry, D. D., Wagner-Weiner, L., McCurdy, D. K., Emery, H. M., Magilavy, D. B., and Kovalesky, A. (1989) Intermittent intravenous cyclophosphamide therapy for lupus nephritis. J. Pediatr. 114(6), 1055–1060.

    Google Scholar 

  201. Frutos, M. A., Rivilla, A., Garcia, I., Burgos, D., Valera, A., Martin-Reyes, G., Cabello, M., and Lopez de Novales, E. (1990) Intravenous pulse cyclophosphamide therapy in severe lupus nephritis. Nefrologia 10(Suppl 5 ), 88–93.

    Google Scholar 

  202. Eiser, A. R., Grishman, E., and Dreznin, S. (1993) Intravenous pulse cyclophosphamide in the treatment of type IV lupus nephritis. Clin. Nephrol. 40, 155–159.

    Google Scholar 

  203. De Bandt, M., Goycochea, M. V., Meyer, O., Delahousse, M., Palazzo, E., M’Bappe, P., and Kahn, M. F. (1994) Treatment of acute systemic lupus erythematosus with intravenous infusions of cyclophosphamide: value and limitations. Ann. Med. Interne (Paris) 145, 75–87.

    Google Scholar 

  204. Chu, S. J., Chang, D. M., Kuo, S. Y., Hsu, C. M., Chen, C. M., and Chang, M. L. (1994) Intermittent intravenous treatment of lupus nephritis with cyclophosphamide: a four-year experience with twenty-four patients. Chung. Kuo. I. Hsueh. Ko. Hsueh. Yuan. Hsueh. Pao. 53, 325–330.

    Google Scholar 

  205. Ruan, J. and Ye, R. G. (1994) Lupus nephritis impact of treatment with cyclophosphamide and traditional Chinese medicine. Chung. Kuo. Chung. Hsi. I. Chieh. Ho. Tsa. Chih. 14, 276–278.

    CAS  PubMed  Google Scholar 

  206. Valeri, A., Radhakrishnan, J., Estes, D., D’Agati, V. Kopelman, R., Pernis, A. Flis, R., Pirani, C., and Appel, G. B (1994) Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin. Nephrol. 42, 71–78.

    Google Scholar 

  207. Sesso, R., Monteiro, M., Sato, E., Kirsztajn, G., Silva, L., and Ajzen, H. (1994) A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis. Lupus 3, 107–112.

    Google Scholar 

  208. Belmont, H. M., Storch, M., Buyon, J., and Abramson, S. (1995) New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis. Lupus 4 (2), 104–108.

    Article  CAS  PubMed  Google Scholar 

  209. Caillard, S., Martin, T., Ginsbourger, M., Weber, J. C., and Pasquali, J. L. (1995) Treatment of lupus glomerulonephritis with intravenous cyclophosphamide. Rev. Med. Interne 16, 413–420.

    Article  CAS  PubMed  Google Scholar 

  210. Yang, L. Y., Chen, W. P., and Lin, C. Y. (1994) Lupus nephritis in children-a review of 167 patients. Pediatrics 94, 335–340.

    CAS  PubMed  Google Scholar 

  211. Conlon, P. J., Fischer, C. A., Levesque, M. C., Smith, S. R., St Clair, E. W., Allen, N. B., Fleming, J. A., and Howell, D. N. (1996) Clinical, biochemical and pathological predictors of poor response to intravenous cyclophosphamide in patients with proliferative lupus nephritis. Clin. Nephrol. 46(3), 170–175.

    Google Scholar 

  212. Malaviya, A. N., Singh, R. R., Sindhwani, R., Singh, Y. N., Ahuja, R. K., Bhuyan, U. N., Khare, S. D., Kumar, A., Malaviya, R., and Negi, P. C., et al. (1992) Intermittent intravenous pulse cyclophosphamide treatment in systemic lupus erythematosus. Indian J. Med. Res. 96, 101–108.

    Google Scholar 

  213. Martinelli, R., Pereira, L. J., Santos, E. S., and Rocha, H. (1996) Clinical effects of intermittent intravenous cyclophosphamide in severe systemic lupus erythematosus. Nephron 74(2),313–317.

    Google Scholar 

  214. Chan, T. M., Li, F. K., Wong, R. W. S., Chan, K. W., and Cheng, I. K. P. (1995) Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisone followed by azathioprine and prednisolone. Nephron 71, 321–327.

    Article  CAS  PubMed  Google Scholar 

  215. Gourley, M. F., Austin, H. A., III, Scott, D., Yarboro, C. H., Vaughan, E. M., Muir, J., Boumpas, T., Klippel, J. H., Balow, J. E., and Steinberg, A. D. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. Ann. Intern. Med. 125, 549–557.

    Article  CAS  PubMed  Google Scholar 

  216. Drinkard, J. P., Stanely, T. M., Dornfeld, L., Austin, R. C., Barnett, E. V., Pearson, C. M., Vernier, R. L., Adams, D. A., Latta, H., and Gonick, H. C. (1970) Azathioprine and prednisone in the treatment of adults with lupus nephritis: clinical, histological, and immunological changes with therapy. Medicine 49, 411–432.

    Article  CAS  PubMed  Google Scholar 

  217. Donadio, J. V., Holley, K. E., and Wagoner, R. D. (1972) Treatment of lupus nephritis with prednisone and azathioprine. Ann. Intern. Med. 77, 829–835.

    Article  PubMed  Google Scholar 

  218. Hahn, B. H., Kantor, O. H., and Osterland, C. K. (1975) Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients. Ann. Intern. Med. 83, 597–605.

    Article  CAS  PubMed  Google Scholar 

  219. Lindahl, G. and Hedfors, E. (1989) Lymphocytic infiltrates and epithelial HLA-DR expression in lip salivary glands in connective tissue disease patients lacking sicca: a prospective study. Br. J. Rheumatol. 28, 293–298.

    Article  CAS  PubMed  Google Scholar 

  220. Nossent, J. C., Bronsveld, W., and Swaak, A. J. (1989) Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively. Ann. Rheum. Dis. 48, 810–816.

    Article  CAS  PubMed  Google Scholar 

  221. McCune, W. J. (1997) Cytotoxic drugs, in Dubois’ Lupus Erythematosus, 5th ed. ( Wallace, D. J. and Hahn, B. H., eds.), Williams and Wilkins, Baltimore, MD, pp. 1163–1180.

    Google Scholar 

Download references

Authors
  1. W. Joseph McCune
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section on Rheumatology, Department of Internal Medicine, The Wake Forest University School of Medicine, Winston-Salem, NC, USA

    Gary M. Kammer MD

  2. Division of Rheumatology and Immunology, Uniformed Services University of Health Sciences, Bethesda, MD, USA

    George C. Tsokos MD

  3. Department of Clinical Physiology, Walter Reed Army Institute of Research, Washington, DC, USA

    George C. Tsokos MD

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

McCune, W.J., Fox, D.A. (1999). Immunosuppressive Agents. In: Kammer, G.M., Tsokos, G.C. (eds) Lupus. Contemporary Immunology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-703-1_37

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-703-1_37

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-5686-9

  • Online ISBN: 978-1-59259-703-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation